#United States #New York #Medical Device #Endometrial Cancer #Utepreva

Utepreva Unveils Groundbreaking Endometrial Sampler

In a significant advancement for women's health, Utepreva LLC has introduced the Utepreva Endometrial Sampler, a patented and FDA 510(k)-cleared single-use device aimed at enhancing the early detection of endometrial cancer. This innovative tool is designed to improve tissue capture and supports critical diagnostic evaluations, crucial for timely intervention.

Understanding the Need for Early Detection

Endometrial cancer is the most prevalent gynecologic malignancy in the United States, with rising incidence and mortality rates. The American Cancer Society estimates that approximately 68,270 new cases will be diagnosed in the current year. Early diagnosis is vital, as survival rates can be as high as 95% when the disease is identified at an early stage, plummeting to below 20% in more advanced stages.

To combat this alarming trend, clinicians require reliable diagnostic tools that can provide high-quality specimens as soon as concerns arise. Traditional single-mechanism devices often limit tissue yield, hindering timely and accurate diagnoses. The Utepreva Endometrial Sampler aims to revolutionize this aspect by integrating three complementary mechanisms to facilitate comprehensive tissue and fluid collection in a single pass.

Superior Design for Enhanced Performance

Unlike conventional endometrial samplers that depend solely on either tissue disruption or suction, the Utepreva sampler combines gentle tissue disruption, controlled suction, and optimized absorption via a sponge tip. This innovative design significantly improves the volume and quality of samples collected.

Preclinical studies conducted by Medical Murray, a respected medical device manufacturer, revealed that Utepreva's sampler captured a significantly greater volume of simulated tissue compared to existing devices. These findings highlight the advancement in performance due to its unique integration of mechanisms, ensuring better tissue disruption and more uniform sampling outcomes.

The sponge tip enhances the device's efficacy further by absorbing fluids and cells from the uterus, while the internal plunger generates suction to minimize sample loss. This performance allows for cytological, histopathological, and molecular analyses from a single sample, enabling a more comprehensive evaluation.

Focus on Patient Comfort and Safety

In addition to improving diagnostic accuracy, Utepreva also emphasizes patient comfort and procedural safety. The device features a slim-profile wand that minimizes discomfort during insertion and removal. An integrated cervical guard prevents over-insertion, while the soft sponge tip reduces the risk of fundal trauma. The entire procedure can be completed in approximately 20 seconds without the need for dilation, sedation, or specialized operating room resources.

Target Patient Population and Future Potential

The Utepreva Endometrial Sampler is primarily advised for symptomatic patients, particularly those experiencing abnormal bleeding or postmenopausal bleeding, as well as women at elevated risk due to factors such as age, obesity, or family history of related cancers. Timely and accurate tissue sampling is critical for these patients to ensure early diagnosis and appropriate intervention.

There is also potential for this device to be integrated into routine gynecological care, serving as a standard method for early detection of uterine cancer, reminiscent of how Pap smears are employed today. As articulated by Dr. Jeanetta Stega, CEO of Utepreva, "Our goal is to enhance not only the detection of pre-cancer but to make a substantial impact on patient outcomes akin to that of Pap smears and mammography."

Availability and Future Developments

The Utepreva Endometrial Sampler is slated for release to healthcare providers in October 2026, with a focus on expanding access to minimally invasive procedures. Additionally, Utepreva plans to showcase this groundbreaking technology at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, ensuring healthcare professionals are well-informed about its innovative capabilities.

For more information on the Utepreva Endometrial Sampler, healthcare providers are encouraged to reach out via email or visit the Utepreva website. As we advance into a new era of diagnostic technology, Utepreva is poised to redefine the landscape of endometrial cancer detection and improve women's health outcomes significantly.